Jenna Karpel

The image shows both company logos of Indica Labs and Source LDPath showcasing the partnership. Since deploying HALO AP® at its Nottingham headquarters, Source BioScience has processed approximately 78,000 cases and 278,000 slides in under nine months with a national rollout now underway that will significantly expand digital pathology capacity across the UK’s outsourced histopathology market.

Source BioScience Selects Indica Labs’ HALO AP® as the Digital Pathology Platform Powering the Future of NHS Outsourcing in the United Kingdom

HALO AP, News, Press Releases / , , , ,

Albuquerque, NM, and Nottingham, September 8, 2026 – Indica Labs, the trusted global leader in AI-powered digital pathology and Source Bioscience, the United Kingdom’s leading provider of histopathology services, today announced Source Bioscience’s successful expansion of its digital pathology operation powered by HALO AP®. Since going live at Nottingham headquarters in October 2025, the organization has demonstrated how an interoperable, scanner-agnostic enterprise platform can eliminate one of the greatest barriers to large-scale digital pathology outsourcing while enabling rapid laboratory growth.

Source BioScience Selects Indica Labs’ HALO AP® as the Digital Pathology Platform Powering the Future of NHS Outsourcing in the United Kingdom Read More »

New zero-click preprocessing automatically identifies invasive carcinoma and excludes DCIS, LCIS, and control tissue before ER, PR, HER2, and Ki67 quantification. Shown here is the HALO Breast IHC AI out put of a stained HER2 slide with AI overlay only in the regions of invasive cancer.

Indica Labs Advances Breast Cancer AI with Zero-Click Tissue Classification Prior to Biomarker Analysis

HALO AP, News, Press Releases / , , , , , , ,

Albuquerque, NM, July 28, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced new intelligent tissue classification capabilities for HALO Breast IHC AI, its AI-powered breast biomarker quantification suite, seamlessly deployed in HALO AP®. This enhanced new version introduces fully automated identification and exclusion of positive control tissue, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), and areas of benign tissue prior to biomarker analysis. This zero-click preprocessing and tissue classification workflow represents a critical step in ensuring accurate and reproducible AI outputs.

Indica Labs Advances Breast Cancer AI with Zero-Click Tissue Classification Prior to Biomarker Analysis Read More »

The latest HALO AP® update is a transformative new version that introduces intelligent workflow orchestration, traceability, and multi-site collaboration to support modern diagnostic environments.

HALO AP 2.5 Advances Digital Pathology with Enhanced Automation, Collaboration, and Scalability

HALO AP, News, Press Releases / , ,

Albuquerque, NM, July 14, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced a new software release designed to streamline and scale digital pathology workflows through enhanced automation, collaboration, and system transparency.

HALO AP 2.5 Advances Digital Pathology with Enhanced Automation, Collaboration, and Scalability Read More »

Prostate Macrodissect AI enables pathologists to identify and quantify tumor-rich regions in prostate specimens with precision. Improving macrodissection accuracy, maximizing NGS tumor content, and reducing QNS failures, a critical advancement in the molecular profiling of the most commonly diagnosed cancer in men.

Indica Labs Expands into Prostate Cancer, Improving NGS ConfidenceThrough Precise Tumor Quantification

HALO AP, News, Press Releases / , ,

Albuquerque, NM, June 30, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the launch of Prostate Macrodissect AI, a clinically validated algorithm designed to automate and quantify tumor content in FFPE prostate tissue specimens. Prostate Macrodissect AI is designed to operate in concert with Indica Labs’ broader HALO Clinical AI suite, enabling laboratories to build end-to-end AI-powered prostate cancer workflows from automated tumor detection and Gleason grading assistance through to optimized macrodissection and genomic test preparation within a single, validated digital pathology platform.

Indica Labs Expands into Prostate Cancer, Improving NGS ConfidenceThrough Precise Tumor Quantification Read More »

HALO AP 2.5 introduces lab logic, a configuration layer that enables labs to tailor HALO AP® to their preferred workflow, enabling any lab, regardless of case volume, to operate like an automated triage engine, continuously analyzing incoming slides; triggering AI-driven actions; and delivering the right cases to the right experts at the right time.

Lab Logic Brings Intelligent Case Orchestration to HALO AP® and HALO AP Dx

Blogs, Clinical, Clinical Products, HALO AP, HALO AP Dx, News / , , ,

HALO AP 2.5 introduces Lab Logic. A configuration layer that enables labs to tailor HALO AP® to their preferred workflow, enabling any lab, regardless of case volume, to operate like an automated triage engine, continuously analyzing incoming slides; triggering AI-driven actions; and delivering the right cases to the right experts at the right time.

Lab Logic Brings Intelligent Case Orchestration to HALO AP® and HALO AP Dx Read More »

A partnership Leica Biosystems, Indica Labs, and Lunit that will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems’ PD-L1 primary antibody (CAL10).

Industry Leaders Leica Biosystems, Indica Labs and Lunit Partner to Develop AI-Powered Computational Pathology Assays for PD-L1 and Emerging Biomarkers

HALO AP, News, Press Releases /

VISTA, California, ALBUQUERQUE, New Mexico, and SEOUL, South Korea — May 26, 2026 — Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Indica Labs, a global leader in AI-powered digital pathology software, today announced a strategic collaboration with Lunit (KRX:328130.KQ), a leading provider of AI solutions for cancer diagnostics and therapeutics, to develop AI-powered image analysis algorithms. The partnership will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems’ PD-L1 primary antibody (CAL10). The new algorithm, Lunit SCOPE PD-L1 CAL10 NSCLC1, is now available through Leica Biosystems’ Aperio AI Store.

Industry Leaders Leica Biosystems, Indica Labs and Lunit Partner to Develop AI-Powered Computational Pathology Assays for PD-L1 and Emerging Biomarkers Read More »

Leica Biosystem and Indica Labs combined Aperio HALO AP DX and Aperio GT 450 DX Scanner for a complete clinical digital pathology ecosystem

Leica Biosystems and Indica Labs Expand Digital Pathology-Powered Diagnostics in the USA with Aperio HALO AP DX Software Launch

HALO AP, HALO AP Dx, News, Press Releases / , , ,

Vista, CA, and Albuquerque, NM, March 31, 2026 – Leica Biosystems, a Danaher company and a global leader in anatomic and digital pathology solutions, and Indica Labs, a global leader in artificial intelligence (AI)-powered digital pathology software, launches Aperio HALO AP DX image management system designed for use with the Aperio GT 450 DX scanner. Together, the Aperio HALO AP DX software and the Aperio GT 450 DX scanner provide a complete, integrated clinical digital pathology solution supporting on‑screen diagnostics across routine pathology workflows in the USA.

Leica Biosystems and Indica Labs Expand Digital Pathology-Powered Diagnostics in the USA with Aperio HALO AP DX Software Launch Read More »

A lap top looking over the Sandia mountains in Albuquerque, NM; showcasing an IHC breast tissue image on the lap top screen with HER2 3+ stanning. Using AI and digital pathology for precision medicine, anytime anywhere.

AI and Digital Pathology in Personalized Medicine: The Past, Present, and Future of Breast Cancer Care

Blogs, Breast IHC AI, HALO AP, News / , , , , ,

AI-powered digital pathology is redefining modern cancer care by extending clinical-grade insights beyond the microscope and enabling standardized, pixel-level analysis to support scalable cancer diagnostics anytime, anywhere.

AI and Digital Pathology in Personalized Medicine: The Past, Present, and Future of Breast Cancer Care Read More »

HALO AP® earned 94.9/100* for overall customer rating in the 2026 Best in KLAS Awards - Global Software report for digital pathology.

KLAS Recognition as a Catalyst for What Comes Next

Blogs, HALO AP, News / ,

We are proud to mark a significant milestone: HALO AP® earned the highest overall customer rating in the 2026 KLAS Global Software report for digital pathology. Because KLAS distinction is driven entirely by direct customer feedback, this recognition reflects the real-world performance, reliability, and impact of our platform in daily pathology practice.

KLAS Recognition as a Catalyst for What Comes Next Read More »

Free Demo
Free Demo
Scroll to Top